SCHEMBL613690

SCHEMBL613690

CCNc1cc(-c2ccncc2)sc1C(N)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.59
DBF4 Q9UBU7 3/20 0.59
IKBKB O14920 12/20 0.54
MKNK2 Q9HBH9 2/20 0.46
MKNK1 Q9BUB5 1/20 0.46
JAK2 O60674 1/20 0.44
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
ROCK2 O75116 1/20 0.41
MAP4K4 O95819 1/20 0.41
GSK3B P49841 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP3A4 P08684 1/20 0.41
BTK Q06187 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613122 0.90 CDC7 (0.57) CDC7DBF4IKBKBJAK2CCNE1
SCHEMBL613433 0.88 PTPN1 (0.48) CDC7DBF4IKBKBCYP1A2CYP2C9
SCHEMBL614144 0.87 CDC7 (0.54) CDC7DBF4IKBKBJAK2CDK2
SCHEMBL612006 0.85 KDM4E (0.52) CDC7DBF4KDM4EALDH1A1HPGD
SCHEMBL612250 0.85 IKBKB (0.70) CDC7DBF4IKBKBJAK2CCNE1
SCHEMBL614262 0.82 CDC7 (0.65) CDC7DBF4IKBKBMKNK2JAK2
SCHEMBL614239 0.81 CDC7 (0.59) CDC7DBF4IKBKBJAK2CCNE1
SCHEMBL611071 0.77 KDM6B (0.50) CDC7DBF4IKBKBKMT2A
SCHEMBL613988 0.75 KDM4E (0.50) KDM4EALDH1A1HPGDKMT2A
SCHEMBL613639 0.75 KDM6B (0.52) CDC7DBF4CDK2ROCK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK CDC7 1/4885DBF4 593/4885IKBKB 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.